Isoform-selective voltage-gated Na+ channel modulators as next-generation analgesics

Future Medicinal Chemistry

Volumn 2, Issue 5, 2010, Pages 775-790

  England, Steve ^a   Rawson, David ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 803467; ACONITINE; ALLETHRIN; ALPHA TOXIN; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; BATRACHOTOXIN; BREVETOXIN; CARBAMAZEPINE; CIGUATOXIN; DELTAMETHRIN; GRYANAOTOXIN; IMIDAZOPYRIDINE DERIVATIVE; LAMOTRIGINE; MU CONOTOXIN; OMEGA CONOTOXIN; OMEGA CONOTOXIN MVIIA; PHENYTOIN; SAXITOXIN; SCORPION VENOM; SEA ANEMONE TOXIN; SODIUM CHANNEL BLOCKING AGENT; TECTIN; TETRODOTOXIN; UNCLASSIFIED DRUG; VERATRIDINE; VOLTAGE GATED SODIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL MODULATOR;

BINDING AFFINITY; CANCER PAIN; CHRONIC PAIN; CIGUATERA; CLINICAL TRIAL; DIZZINESS; DRUG BINDING; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; NAUSEA; NEUROPATHIC PAIN; NOCICEPTIVE RECEPTOR; NONHUMAN; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; REVIEW; UNSPECIFIED SIDE EFFECT;

ANALGESICS; ANIMALS; DRUG DISCOVERY; HUMANS; PAIN; PROTEIN ISOFORMS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 77953427138     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.26     Document Type: Review

References (69)

1. Finnerup NB, Otto M, McQuay HJ et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118 (3), 289-305 (2005).
2. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 57 (4), 397-409 (2005). □□ Still one of the best reviews on sodium channel structure-function and nomenclature.
3. Elinder F, Nilsson J, Arhem P. On the opening of voltage-gated ion channels. Physiol. Behav. 92 (1-2), 1-7 (2007).
4. + channel. Nature 423 (6935), 33-41 (2003). □□ One of the key papers that addressed the issue of the 3D structure of an ion channel.
5. + channel. Nature 423 (6935), 42-48. (2003).
6. Ulbricht W. Sodium channel inactivation. molecular determinants and modulation: Physiol. Rev. 85 (4), 1271-1301 (2005).
7. Catterall WA, Cestèle S, Yarov-Yarovoy V et al. Voltage-gated ion channels and gating modifier toxins. Toxicon. 49 (2), 124-141 (2007).
8. Velazquez JL, Huo JZ, Dominguez LG et al. Typical versus atypical absence seizures. network mechanisms of the spread of paroxysms. Epilepsia. 48 (8), 1585-1593 (2007).
9. Ravens U. Novel pharmacological approaches for antiarrhythmic therapy. Naunyn Schmiedebergs Arch. Pharmacol. (2010) (Epub ahead of print).
10. Porto GG, Vasconcelos BC, Gomes AC et al. Evaluation of lidocaine and mepivacaine for inferior third molar surgery. Med. Oral Patol. Oral Cir. Bucal. 12 (1), E60-E64 (2007).
11. + channels. Proc. Natl Acad. Sci. USA 93 (17), 9270-9275 (1996).
12. Fozzard HA, Lee PJ, Lipkind GM. Mechanism of local anesthetic drug action on voltage-gated sodium channels. Curr. Pharm. Des. 11 (21), 2671-2686 (2005). □□ Important description of likely mechanisms by which small molecules interact with sodium channels.
13. + channels in rat hippocampal neurones. Br. J. Pharmacol. 121 (6), 1231-1238 (1997).
14. de Curtis M, Avanzini G. Interictal spikes in focal epileptogenesis. Prog. Neurobiol. 63 (5), 541-567 (2001).
15. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am. J. Med. 122 (10 Suppl), S22-32 (2009).
16. Baron R. Neuropathic pain: a clinical perspective. Handb. Exp. Pharmacol. 194, 3-30 (2009).
17. Wiffen PJ, Collins S, McQuay HJ, Carroll D et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst. Rev. (1), CD001133 (2010). □□ Meta-analysis that reviews the efficacy of nonselective sodium channel modulators in chronic pain.
18. England S, de Groot MJ. Subtype-selective targeting of voltage-gated sodium channels. Br. J. Pharmacol. 158 (6), 1413-1425 (2009).
19. Black JA, Dib-Hajj S, McNabola K et al. Spinal sensory neurons express multiple sodium channel α-subunit mRNAs. Brain Res. Mol. Brain Res. 43 (1-2), 117-131 (1996). □ First indication that primary afferent neurones expressed a number of transcripts for sodium channels.
20. Dib-Hajj SD, Black JA, Waxman SG. Voltage-gated sodium channels: therapeutic targets for pain. Pain Med. 10 (7), 1260-1269 (2009).
21. England S. Voltage-gated sodium channels: the search for subtype-selective analgesics. Expert Opin. Investig. Drugs 17 (12), 1849-1864 (2008).
22. v 1.3 were different in rodents and humans.
23. Waxman SG, Kocsis JD, Black JA. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J. Neurophysiol. 72 (1), 466-470 (1994).
24. Dib-Hajj SD, Fjell J, Cummins TR et al. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 83 (3), 591-600 (1999). □ Good description of the regulation of a sodium channel with damage to peripheral nerves.
25. Cummins TR, Waxman SG. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J. Neurosci. 17 (10), 3503-3514 (1997).
26. v 1.3 sodium channels: rapid repriming and slow closed-state inactivation display quantitative differences after expression in a mammalian cell line and in spinal sensory neurons. J. Neurosci. 21 (16), 5952-5961 (2001).
27. v 1.3 null mutant mice. Mol. Pain 2, 33 (2006).
28. v 1.7.
29. v 1.7, to congenital insensitivity to pain.
30. v 1.7 gene underlie congenital indifference to pain in multiple human populations. Clin. Genet. 71 (4), 311-319 (2007). □□ Similar to the study by Cox et al. but more extensive, including data from nine families from seven different nationalities.
31. Drenth JP, Te Morsche RH, Mansour S et al. Primary erythermalgia as a sodium channelopathy: screening for SCN9A mutations: exclusion of a causal role of SCN10A and SCN11A. Arch. Dermatol. 144 (3), 320-324 (2008).
32. v 1.7 currents.
33. v1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 128 (8), 1847-1854 (2005).
34. Hayden R, Grossman M. Rectal, ocular, and submaxillary pain; a familial autonomic disorder related to proctalgia fugaz: report of a family. AMA J. Dis. Child 97 (4), 479-482 (1959).
35. Fertleman CR, Ferrie CD, Aicardi J et al. Paroxysmal extreme pain disorder (previously familial rectal pain syndrome). Neurology 69 (6), 586-595 (2007).
36. Jarecki BW, Piekarz AD, Jackson JO et al. Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents. J Clin Invest. 120 (1), 369-378 (2010).
37. Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 379 (6562), 257-262 (1996).
38. Akopian AN, Souslova V, England S et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat. Neurosci. 2 (6), 541-548 (1999).
39. v1.8. Pain 95 (1-2), 143-152 (2002).
40. v1.8 is essential for pain at low temperatures. Nature 447 (7146), 855-858 (2007).
41. 3H]Batrachotoxinin A 20 α-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs. J. Med. Chem. 28 (3), 381-388 (1985).
42. González JE, Maher MP. Cellular fluorescent indicators and voltage/ion probe reader (VIPR) tools for ion channel and receptor drug discovery. Receptors Channels (5-6), 283-295 (2002).
43. v1.2 sodium channels using the FLIPR Vm dye: on-target and off-target effects of diverse pharmacological agents. J. Biomol. Screen. 11 (1), 29-39 (2006).
44. Neher E, Sakmann B. The patch clamp technique. Sci Am. 266 (3), 44-51 (1992).
45. Dunlop J, Bowlby M, Peri R et al. Highthroughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat. Rev. Drug Discov. 7 (4), 358-368 (2008).
46. v1.6 voltage-dependent sodium channel. Am. J. Physiol. 293 (2, Pt 1), C783-9 (2007).
47. Middleton RE, Warren VA, Kraus RL et al. Two tarantula peptides inhibit activation of multiple sodium channels. Biochemistry 41, 14734-14747 (2002).
48. v 1.7 reported.
49. Xiao Y, Luo X, Kuang F et al,. Synthesis and characterisation of huwentoxin-IV, a neurotoxin inhibiting central neuronal sodium channels. Toxicon. 51, 230-239 (2008).
50. Xiao Y, Bingham J-P, Zhu W et al. Tarantula Huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4. J. Biol. Chem. 283, 40, 27300-27313 (2008).
51. v 1.7 sodium channels and a potent analgesic (Poster 45). Presented at: IST 15th World Congress on Animal, Plant and Microbial Toxins. Leuven, Belgium, 7-10 September 2008.
52. Li D, Xiao Y, Xu, X et al.. Structure-activity relationships of Hainantoxin-IV and structure determination of active and inactive sodium channel blockers. J. Biol. Chem. 279, 36, 37734-37740 (2004).
53. + channels. FEBS Lett. 579, 4181-4186 (2005).
54. v 1.8 and has a long lasting analgesic activity. Biochemistry 45, 7404-07414, (2006).
55. Wang CZ, Zhang H, Jiang H et al. A novel conotoxin from Conus striatus, mu SIIIA, selectively blocking rat TTX-R sodium channels. Toxicon. 47, 122-132 (2006).
56. Green BR, Catlin P, Zhang MM et al. Conotoxins containing non-natural backbone spacers: cladistic-based design, chemical synthesis and improved analgesic activity. Chem. Biol. 14, 399-407 (2007).
57. Craik, DJ, Adams DJ. Chemical modifications of conotoxins to improve stability and activity. Chem. Biol. 2, 7, 457-468 (2007).
58. v 1.7.
59. Williams BS, Felix JP, Priest BT et al. Characterisation of a new class of potent inhibitors of voltage-gated sodium channels. Biochemistry 46, 14693-14703 (2007).
60. v 1.7 sodium channel blocker reverses hyperalgesia and allodynia on rat models of inflammatory and neuropathic pain. Anesthesia Analgesia, 109, 32, 951-958 (2009).
61. v 1.7 channel blockers. Bioorg. Med. Chem. Lett. 18, 1696-1701, (2008).
62. Ok D, Li C, Abbadie C et al. Synthesis and SAR of 1, 2-trans- (1-hydroxy-3-phenylprop-1-yl) cyclopentane carboxamide derivatives, a new class of sodium channel blockers. Bioorg. Med. Chem. Lett. 16, 1358-1361 (2006).
63. Kort ME, Drizin I, Gregg RJ et al. Discovery and biological evaluation of 5-aryl-2-furfuramides. J. Med. Chem. 51, 407-416 (2008).
64. v 1.8 compound.
65. Kort ME, Drizin I, Scanio M J C et al. Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg. Med. Chem. 16, 6379-6386 (2008).
66. v 1.8 channel. J. Biol. Chem. 284 (16), 10523-10536 (2009).
67. v 1.8 blockers for the treatment of chronic mixed pain. Presented at: 20th Symposium on Medicinal Chemistry in Eastern England. University of Hertfordshire Fielder Centre, Hatfield, UK, 30 April 2009.
68. + channel. Science 309 (5736), 897-903 (2005).
69. + channel in a lipid membrane-like environment. Nature 450 (7168), 376-382 (2007).